The WIN Consortium and New York University Cancer Institute Collaborate
News Feb 12, 2013
This new partnership will ensure that NYU Cancer Institute play an active and vital role in WIN’s efforts to translate the most innovative approaches in personalized cancer medicine into patient care worldwide. NYU Cancer Institute is an NCI-designated Comprehensive Cancer Center for more than 33 years, a prestigious ranking conferred to select institutions characterized by scientific excellence, the capability to integrate a diversity of research approaches, and leadership in NCI-funded research efforts.
The WIN Consortium was created to spur collaboration between all stakeholders in personalized cancer medicine and to carry out cross-sector, worldwide clinical trials through the Consortium’s global network of academic and industry partners. With significant ongoing oncologic clinical trials, established multidisciplinary research structures, and a track record of successful research partnerships, NYU Cancer Institute is poised to play an integral role in the Consortium.
“NYU Cancer Institute joining WIN is an important step in the continued development of the Consortium’s capabilities and potential,” stated WIN Consortium Chairman Dr. John Mendelsohn. “The clear strengths NYU brings – experience serving a diverse patient population, excellence in disease-focused and basic science research, and committed, involved leadership – will help speed the translation of personalized cancer medicine innovations into the treatment of cancer patients.”
Dr. William Carroll, Director of the NYU Cancer Institute, noted, “This partnership will provide increased opportunities for the NYU Cancer Institute to play a strong role in innovative, global clinical trials and projects. We believe that this collaboration is strategically significant to advancing the practice of personalized cancer medicine and we look forward to active participation in the Consortium.”
Founded in 2010 on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of 29 leading academic, pharmaceutical, biotech, healthcare IT, and patient advocacy organizations working to accelerate the pace and reduce the cost of translating the most promising advances in genomic-based cancer research into the standard of patient care worldwide. WIN is a non-governmental, not-for-profit organization headquartered in Paris.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.
Researchers Zoom in on DNA Code Being Read in CellsNews
Scientists have unveiled incredible images of how the DNA code is read and interpreted – revealing new detail about one of the fundamental processes of life. The mechanism for reading DNA and decoding it to build proteins for their needs is common to all animals and plants, and is often hijacked by cancer. The discovery of exactly how the molecular mechanism works, could open up new approaches to cancer treatment.READ MORE